Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06360354
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-04-08
Brief Title:
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal Biliary Tract or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase MTAP-Deletion
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal Biliary Tract or Pancreatic Cancers With Homozygous MTAP-deletion
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to determine maximum tolerated dose MTD or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase MTAP-deleted gastrointestinal biliary tract or pancreatic cancers The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal biliary tract or pancreatic cancers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None